<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 28.4</label>
 <caption>
  <p>Comparison of three FDA-approved HIV-1 viral load assays commonly used in assessment</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Product</th>
    <th>Amplicor</th>
    <th>Versant</th>
    <th>NucliSENS</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Principle (company)</td>
    <td>Rt-PCR (Roche)</td>
    <td>b DNA (Bayer)</td>
    <td>NASBA (bioMerieux)</td>
   </tr>
   <tr>
    <td>Method of amplification</td>
    <td>Exponential amplification of the target molecules</td>
    <td>Linear amplification of the signal</td>
    <td>Method of amplification</td>
   </tr>
   <tr>
    <td>Genomic region targeted</td>
    <td>Gag</td>
    <td>Pol</td>
    <td>Gag and pol</td>
   </tr>
   <tr>
    <td>Technical platform</td>
    <td>Microplate can be upgraded to real-time analysis</td>
    <td>Microplate</td>
    <td>Microplate can be upgraded to real-time analysis</td>
   </tr>
   <tr>
    <td>Advantage /Disadvantage</td>
    <td>Less false-positive than b DNA</td>
    <td>Wide range/time consuming</td>
    <td>For many types of sample</td>
   </tr>
   <tr>
    <td>Dynamic range</td>
    <td>50 (V1.0) or 400 (V1.5) to 750,000 copies/ml</td>
    <td>b DNA V3.0: 75–500,000 copies/ml</td>
    <td>NucliSENS HIV-1 QT: 176-3, 500,000 copies/ml</td>
   </tr>
   <tr>
    <td>Sample amount required</td>
    <td>0.2–0.5 ml</td>
    <td>1 ml</td>
    <td>10 μl–2 ml</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
